The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Results for Anorexia Nervosa with Psilocybin.

2.

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

3.

Two medications might work better for breast cancers that are resistant to one.

4.

The most precise research tools for the deadliest blood cancer have been developed.

5.

Error on the MGUS-Autoimmune Disease Association.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot